Aurobindo Pharma has been issued an establishment inspection report (EIR) from the US Food and Drug Administration (FDA) for one of its manufacturing facilities in Telangana, India.

The Indian pharma company said that the FDA completed an inspection at its Unit VII, an oral manufacturing facility in Jadcherla town and issued the EIR.

The report mentioned the inspection as a voluntary action initiated (VAl) by the regulator. Voluntary Action Indicated is mentioned when the FDA finds objectionable conditions or practices but is not ready to take or recommend any administrative or regulatory action.

  Aurobindo Pharma, India, Jadcherla, Telangana, US Food and Drug Administration